Cantley, professor of Systems Biology at Harvard Medical School and chief of the Division of Signal Transduction at Beth Israel Deaconess Medical Center, both in Boston, will receive a cash prize of €75,000 with the award.
"Dr. Cantley's contributions to cancer are profound," said AACR Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.). "In addition to opening up a key regulatory pathway of oncogenesis that is manifested in many, if not most human malignancies, they also provide opportunities for drug targeting of PI3K or downstream effectors.
"Indeed, many such drugs are in clinical trials for cancer and are expected to also find use in treatment of inflammatory and allergic diseases."
Research from Cantley's laboratory and others has revealed that PI3K also is a significant factor in insulin signalling and in immune cell signalling. As a result, pharmaceutical intervention in the PI3K pathway is being explored in a variety of diseases, including cancer, diabetes and immune diseases.
"I am honoured to have received this award indicating an international recognition of the importance of PI 3-kinase in human cancer," Cantley said.
"Over the past 20 years, our understanding of PI 3-kinase has progressed from an unusual lipid kinase activity that we found associated with oncogene products to the central player in a network that controls the growth and survival of cancer cells. There is now much optimism that the elucidation of this network is revealing effective targets for pharmaceutical intervention in a wide variety of human cancers."
MEDICA.de; Source: American Association for Cancer Research